Pharma major AstraZeneca Plc priced its euro medium-term notes at an aggregate price of €2.20bn ($2.53bn).
Proceeds from the issuance would be utilized for general corporate purposes and repayment of debt.
The debt was issued in three tranches which are as follows:
- €500m, five-year, fixed rate notes with a coupon of 0.25%,
- €900m, eight-year fixed rate notes with a coupon of 0.75%, and
- €800m, twelve-year fixed rate notes with a coupon of 1.25%.
The notes would be issued to institutional investors outside the U.S., the company said.